Notice of Contract Award - Orexo US, Inc. BARDA-BAA-OrexoNotice

Solicitation BARDA-BAA-OrexoNotice Copied Notice ID 2f2165fde1f3420891121bb88d554782 Copied HEALTH AND HUMAN SERVICES, DEPARTMENT OF — BARDA - ASPR / DAAPPO / BARDA DCMA

SAM.gov

Posted

Sep 26, 2025

Deadline

Sep 24, 2025

Set-aside

NONE

NAICS

541714

PSC

AN13

Summary

AI-generated · Sep 28, 2025

Orexo US, Inc. received a contract to conduct the clinical development of OX390 (atipamezole) as a human-use alpha-2 agonist reversal agent, intended to counteract the sedative effects of xylazine, medetomidine, and other alpha-2 agonists increasingly found in combination with IMF. This is an award notice for contract 75A50125C00010.

Award Notice for Orexo US, Inc. (Contract 75A50125C00010). Clinical development of OX390 (atipamezole) as an ?2 agonist reversal agent for human use to counteract the sedative effects of xylazine, medetomidine, and other ?2 agonists that are increasingly found in combination with IMF.

From Special Notice posted on Sep 26, 2025

Notice history

Special Notice LATEST Posted Sep 26, 2025 View

Details

Solicitation number BARDA-BAA-OrexoNotice

Notice ID 2f2165fde1f3420891121bb88d554782

Notice type Special Notice

Product / Service (PSC) AN13

NAICS 541714

Set-aside No Set aside used

Place of performance Morristown, New Jersey

Archive date Oct 09, 2025

Award Information

Not yet awarded

Documents

Document 1

Contacts

primary

Jonathan Gonzalez, Contracting Officer

Phone

secondary

Joann Kambaja, Contract Specialist

Phone

Agency

HEALTH AND HUMAN SERVICES, DEPARTMENT OF

OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE

BARDA - ASPR / DAAPPO / BARDA DCMA

Place of Performance

Morristown, New Jersey 07960
USA

Dates

Posted Sep 26, 2025 10 months ago

Last Updated Aug 06, 2026 1 day ago

Due Sep 24, 2025 10 months ago